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We have reached a watershed moment in Europe in our efforts to ensure
increased survival and better outcomes for cancer patients. The EU Cancer
Mission and the European Beating Cancer Plan together provide an unri-
valled opportunity to make significant inroads into a disease that kills over
1.7 million European citizens annually. Harnessing these twin pillars of
cancer research and cancer control can be transformative for the European
cancer community and in particular for the European cancer patient. How-
ever, from a research perspective, in order to fully realise these benefits, we
need to ensure that all aspects of the cancer continuum are addressed. Pre-
vious research efforts have focussed more on the diagnosis and treatment
of cancer, whereas cancer survivorship, to date, has been overlooked. Here,
we aim to redress this balance, by identifying the key challenges in cancer
survivorship research that need to be addressed and proposing a series of
recommended solutions, which, if acted upon, would deliver significant
benefits for the nearly 20 million cancer survivors in Europe. To achieve
this, we propose the development of a clearly articulated and sustainably
funded European Cancer Survivorship Research and Innovation Plan.
Embedding this plan within the framework of the EU Cancer Mission
would be transformative for cancer survivors and society.
1. Introduction
Despite the undoubted progress that has been made in
improving cancer control and increasing cancer
survivorship over the last 50 years, the significant chal-
lenges that still persist across the cancer continuum
have led to a renewed global focus on a disease that
kills over 10 million citizens worldwide each year
Abbreviations
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(https://gco.iarc.fr/). Critically, there has been a wel-
come realisation that research and innovation must be
a key cornerstone of modern cancer control, with an
undeniable body of evidence, indicating that those can-
cer patients who are treated in research-active hospi-
tals or centres achieve better outcomes than those who
are not [1]. In the United States, the launch of the
Cancer Moonshot and its continuing implementation
has resonated with patients, clinicians and scientists,
acting as a crucial driver in positioning research and
innovation at the forefront of the fight against cancer
[2]. In Europe, steady progress in cancer research and
its translation into effective cancer care has led to
improved outcomes for cancer patients [3], including
childhood and young adult patients. However, the age-
ing population demographic, allied to genomic, envi-
ronmental and lifestyle factors that will contribute to
an increased incidence of cancer in the next 15–
20 years, together with the challenges of treating the
disease as it becomes more aggressive, mean that can-
cer and its control must be the critical focus for
research and innovation implementation, health service
delivery and health policy efforts over the coming
years.
2. Ensuring cancer is at the top of the
European health and research agenda
In Europe, the importance of ensuring that cancer is
at the top of the health and research agenda has been
recognised at the very highest political level. The Presi-
dent of the European Commission, Ursula Van Der
Leyden, has emphasised that health is a clear priority
within the agenda of the current European Parliament
and has tasked the EU Commissioner for Health and
Food Safety, Stella Kyriakides, to ensure that cancer
is a disease of key focus in the European Commis-
sioner’s overarching strategy for Health (https://ec.e
uropa.eu/health/non_communicable_diseases/events/
ev_20200204_en). The recent launch of Europe’s Beat-
ing Cancer Plan on the 3 February 2021 (https://ec.e
uropa.eu/health/sites/health/files/non_communicable_d
iseases/docs/eu_cancer-plan_en.pdf) underpins the
commitment to cancer and represents a huge opportu-
nity to deliver optimal care for cancer patients and
enhanced support for cancer survivors across the
European continent. From a research perspective, the
EU Cancer Mission, one of only 5 Research Missions
of the EU (https://ec.europa.eu/info/horizon-europe/
missions-horizon-europe_en), emphasises the need for
a real step change in cancer research activity in Europe
[4], supported through the upcoming Horizon Europe
research funding programme. The Lancet Oncology
European Cancer Groundshot Commission [5] also
highlights the absolute primacy of cancer research and
emphasises how deployment of data intelligence to
identify the key research gaps and challenge that we
face can illuminate the path to a vibrant European
cancer research agenda, with a particular focus on
Central and Eastern Europe (CEE). Additionally, the
adverse impact of the COVID-19 pandemic on cancer
patients, cancer services and cancer research has been
significant [6]; it is vital that the European Beating
Cancer Plan and the EU Cancer Mission address both
the short and longer term effects of the pandemic
aggressively. In this regard, the recent launch by the
European Cancer Organisation’s Special Focussed
Network on COVID-19 and Cancer of a 7-point plan
to ‘Build Back Better’ (https://cancerworld.net/build
ing-back-cancer-services-after-covid-19-european-cance
r-organisation-plan/) can be both instructive and trans-
formative.
3. Cancer in Europe: responding to
the survivorship challenge
Although much progress has been made in delivering
improved cancer control in Europe, there are still
many challenges to be overcome, a number of which
relate to the unequal nature of the cancer burden and
its control in different parts of Europe, particularly in
CEE. These inequalities [7] and disparities [8] that
European citizens and cancer patients have been expe-
riencing, allied to the increasing impact of the social
determinants of health [9], mean that we must redou-
ble our efforts to ensure that the following key areas
are addressed from cancer control, cancer research and
cancer policy perspectives:
i. that cancer prevention receives a higher priority from
a public health, research and policy perspective;
ii. that citizens with suspicion of cancer are diagnosed
at the earliest possible stage of their illness;
iii. that patients with cancer receive the optimal treat-
ment and supportive care in a timely fashion, that is
underpinned by the latest research and innovation;
iv. that cancer survivors are adequately supported in a
holistic way to ensure that they experience the best
possible quality of life, receive the appropriate
rehabilitation support that they require and that
there is a clear focus on their full reintegration into
society without discrimination.
This last area of focus is particularly important in
the context of this paper, allied to the role of Euro-
pean political leadership in delivering fit for purpose,
integrated and effective European Beating Cancer and
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EU Cancer Mission plans which include a focus on
cancer survivorship. In general, the overarching atten-
tion of the European scientific and clinical communi-
ties to date has been more on diagnosis and treatment
of cancer than on living with and beyond cancer.
However, the fact that nearly 20 million citizens in
Europe have survived cancer (https://www.europeanca
nceracademy.eu/cancer-survivorship) means that we
must greatly enhance our engagement with cancer sur-
vivors and the cancer survivorship agenda, in order to
ensure that the specific survivorship challenges and
needs are adequately addressed, particularly with
respect to survivorship research, holistic support for
survivors and active rehabilitation and reintegration
into society. Survivorship, rehabilitation and reintegra-
tion into society are key pillars of the European Can-
cer Organisation’s European Code of Cancer Practice
[10]. It is imperative that each cancer patient must
have a survivorship care plan [11], while the suggestion
for a Cancer Survivor Smart Card or Passport also
merits further attention, as exemplified by the Sur-
vivorship Passport in paediatric oncology brought for-
ward through continued work in a number of EU
projects [12]. A recently published study highlights the
importance on capturing detailed European data on
cancer cure and quality of life for cancer survivors
[13].
In this paper, as members of the Cancer Survivor-
ship Committee of the European Academy of Cancer
Sciences, we focus our attention and expertise on iden-
tifying the specific survivorship research and innova-
tion challenges that Europe is currently facing and
propose a series of cogent recommended solutions that
can be adopted by and embedded within the frame-
work of the EU Cancer Mission.
4. Enhancing cancer survivorship
through research and innovation
Previously, in this journal, we have reviewed the cur-
rent state of knowledge in-depth in relation to cancer
survivorship and identified specific research areas that
should be developed, in order to inform future inter-
ventions to support the European cancer survivor and
the survivorship agenda in Europe [14]. Additionally,
as part of a wider focus on cancer research within
Horizon Europe, we highlighted the importance of
ensuring that survivorship research is an active compo-
nent of the EU Cancer Mission [11]. The evidence base
from these two papers informs this current publica-
tion. Here, we prioritise three distinct Cancer Survivor-
ship Research and Innovation Pillars that we propose
should be the areas of focus for a European Cancer
Survivorship Research and Innovation Plan. Within
these pillars, we delineate a series of challenges that
currently limit progress in the cancer survivorship
domain (Text Boxes 1–3) and propose a series of rec-
ommended solutions that will firmly embed cancer sur-
vivorship research and innovation within the
overarching and evolving framework of the EU Cancer
Mission.
The three Cancer Survivorship Research and Inno-
vation Pillars that we have identified are as follows:
 The Medical Cancer Survivorship Research and
Innovation Pillar
Challenges within the Medical Cancer Survivorship
Research and Innovation Pillar
Challenge 1.1: Cancer survivorship research is not
sufficiently integrated into cancer research activity in
Europe.
Challenge 1.2: Lack of a European Cancer Survivorship
Research and Innovation Plan.
Challenge 1.3: Lack of robust data intelligence to
underpin cancer survivorship research prioritisation.
Challenge 1.4: Research activities often do not underpin
cancer survivors’ needs.
Challenge 1.5: Lack of integration of patients into the
research and innovation agenda, with limited active
involvement in survivorship research.
Challenge 1.6: Limited interdisciplinary research activity
in the survivorship domain and a paucity of survivor-
ship research tools.
Challenge 1.7: Lack of appreciation of the potential
value of the international collaborative research dimen-
sion.
Challenge 1.8: Paucity of specific research programmes
for children, adolescents and young adult survivors.
Challenge 1.9: Lack of focus on Palliative/End of Life
research.
Challenge 1.10: Improve cancer survival such that an
average of 70% survival is achieved across Europe by
2035 (the 70:35 vision).
Text Box 1
Delineating the challenges within the Politico-Legal Cancer
Survivorship Research and Innovation Pillar
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 The Socio-economic Cancer Survivorship Research
and Innovation Pillar
 The Politico-Legal Cancer Survivorship Research
and Innovation Pillar
For each of these Cancer Survivorship Research and
Innovation Pillars, we highlight a series of challenges
that should be placed firmly within scope of the EU
Cancer Mission, accompanied by cogent and relevant
solutions that can be successfully implemented across
the different upcoming phases of the Horizon Europe
research funding programme.
4.1. Addressing the Medical Cancer Survivorship
Research and Innovation Pillar
The challenges posed in the medical cancer survivor-
ship research and innovation domain and the recom-
mended solutions proposed are outlined below:
Survivorship challenge 1.1: Cancer survivorship
research is not sufficiently integrated into cancer
research activity in Europe.
Recommended solution 1.1: Ensure that the cancer
survivorship research agenda is an integrated compo-
nent of the translational cancer research continuum in
Europe, so that side effects and late sequelae of treat-
ment can be understood and mitigated against,
underpinning a health-related quality of life (HRQoL)
focussed research and innovation agenda. Evaluation
of late effects/late complications after cancer treatment
ideally should start at the beginning of each clinical
trial/cancer treatment intervention by early inclusion
of late effect end-points. Following conclusion of the
clinical study, there should be a sustainable system
whereby late effects are specifically monitored through
long-term follow-up, allowing timely capture of new
events or complications.
Survivorship challenge 1.2: Lack of a European Can-
cer Survivorship Research and Innovation Plan.
Recommended solution 1.2: Actively support a Euro-
pean Cancer Survivorship Research and Innovation
Plan, to be embedded within the EU Cancer Mission,
with the ambitious aim of achieving an average of
70% cancer survival in Europe by 2035 (70:35 vision)
[15]. The European Society for Paediatric Oncology
(SIOPE) manifesto to ‘Cure more, cure better’ (https://
worldspanmedia.s3-eu-west-1.amazonaws.com/media/
siope/PDF/SIOP-Manifesto-A5-vFINAL.pdf) is highly
relevant here and can contribute to this overall vision.
Survivorship challenge 1.3: Lack of robust data intel-
ligence to underpin cancer survivorship research prioriti-
sation.
Recommended solution 1.3: Inform prioritisation of
cancer survivorship research by performing compre-
hensive landscape scanning of existing cancer survivor-
ship activities and deploying robust clinical and
epidemiologic data to identify, quantify and prioritise
Challenges within the Socio-Economic Cancer Survivor-
ship Research and Innovation Pillar
Challenge 2.1: Lack of detailed knowledge of the
specific social determinants of cancer inequalities that
impact on cancer survivorship.
Challenge 2.2: Paucity of relevant tools to assess health-
related quality of life (HRQoL) in cancer survivors.
Challenge 2.3: Lack of accurate robust data on the
economic burden of cancer for cancer survivors.
Challenge 2.4: Paucity of data on the impact and cost-
effectiveness of interventions for cancer survivors.
Challenge 2.5: Lack of financial support for cancer
survivorship research at European level.
Challenge 2.6: Limited integration of social issues into
cancer survivorship research activities.
Challenges within the Politico-Legal Cancer Survivorship
and Innovation Pillar
Challenge 3.1: Limited detailed intelligence on the legal
aspects of discrimination for cancer survivors.
Challenge 3.2: Lack of research on the legal aspects of
reintegration of cancer survivors back into society.
Challenge 3.3: Paucity of research that specifically
focusses on the activities and requirements of Cancer
Patient Advocacy Groups.
Challenge 3.4: Lack of knowledge of the stigma asso-
ciated with cancer.
Challenge 3.5: Lack of specific research on survivorship
support for patients and for patient empowerment.
Text Box 2
Delineating the challenges within the Socio-Economic Cancer
Survivorship Research and Innovation Pillar
Text Box 3
Delineating the challenges within the Politico-Legal Cancer
Survivorship Research and Innovation Pillar
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specific survivorship research gaps. In this regard,
while clinical trial data are highly relevant, survivor-
ship research should also include patients routinely
treated within healthcare systems, focussing on clinical
effectiveness which should be assessed, ideally, on
population-based patient groups. In order to achieve
this and assure effective research activities for all can-
cer survivors, clinical registries with quality-assured
data are required, combined with long-term follow-up
to facilitate compilation of data across centres, regions
and countries. These registries should collect data on
HRQoL. This could form part of the European Health
Data Space (https://ec.europa.eu/info/law/better-regula
tion/have-your-say/initiatives/12663-A-European-Hea
lth-Data-Space-), with particular focus on data relating
to survivorship. Define different cancer survivor sub-
groups (including the different ages of survivors, both
at treatment and at follow-up in their survivorship tra-
jectory) on the basis of both clinical and epidemiologi-
cal data in order to ensure that the survivorship
research activity undertaken identifies the most appro-
priate tailored care and support is delivered to each
cancer survivor subgroup as effectively as possible.
Survivorship challenge 1.4: Research activities often
do not underpin cancer survivors’ needs.
Recommended solution 1.4: In prioritising a Euro-
pean Cancer Survivorship Research and Innovation
Plan, it is critical to ensure that the chosen priorities
clearly reflect survivors’ specific long-term needs (in
areas including fertility preservation, reconstruction
surgery, mental health, dental health, rehabilitation
and others) and that the research is focussed on the
cancer survivor community’s approved priority areas.
Early confirmation of survivors’ needs and integration
of these needs into the decision-making process should
help inform the key components of, for example,
access to rehabilitation (physical, psychological, social,
cognitive, nutritional, sexual etc.) and ensure that the
European Cancer Survivorship Research and Innova-
tion Plan aligns directly to survivors’ needs and
wishes. In addition, it is paramount that cancer sur-
vivors are active participants in both the design and
the implementation of the different components of a
European Cancer Survivorship Research and Innova-
tion Plan.
Survivorship challenge 1.5: Lack of integration of
patients into the research and innovation agenda, with
limited patient involvement in survivorship research.
Recommended solution 1.5: As also highlighted in
Survivorship Challenge 1.4, ensure that cancer sur-
vivorship research and innovation occur in closer col-
laboration with healthcare professionals, cancer
survivors and their patient advocates, mandating that
cancer survivors are embedded in the research activi-
ties and both provide and receive feedback on the
research being performed or proposed. Cocreation of
the research and innovation agenda between the can-
cer survivor community and health professionals is
crucial – cancer survivors must be ‘active partici-
pants’ rather than ‘passive recipients’ in the process.
Additionally, it is important to ensure that all initia-
tives on survivorship research and innovation should
be harmonised in order to avoid fragmentation of
efforts and resources.
Survivorship challenge 1.6: Limited interdisciplinary
research in the survivorship domain and a paucity of sur-
vivorship research tools.
Recommended solution 1.6: Promote an interdisci-
plinary survivor-centred approach for specific survivor-
ship research programmes. Develop and elaborate new
tools to facilitate survivorship research, including the
assessment of the health and well-being of cancer sur-
vivors. Bringing together different research communi-
ties with added-value insights provides the best
opportunities to deliver optimal solutions that most
benefit cancer survivors.
Survivorship challenge 1.7: Lack of appreciation of
the potential value of the international collaborative
research dimension.
Recommended solution 1.7: A comprehensive cancer
survivorship research and innovation programme
requires international collaboration to help set
research priorities, ensure successful implementation
and benchmark findings (e.g. ensuring patient-reported
outcomes are captured, reported and compared with
data from international partners), so it is important
that the European Cancer Survivorship Research and
Innovation Plan is both designed and pursued in col-
laboration with international partners.
Survivorship challenge 1.8: Paucity of specific
research programmes for children, adolescents and
young adult survivors.
Recommended solution 1.8: It is critically important
that any European Cancer Survivorship Research and
Innovation Plan specifically addresses the needs of
children, adolescents and young adults. It is recom-
mended that the EU Cancer Mission includes the
ambition to develop age-adapted research pro-
grammes, informed by consultation, that best meet the
needs of children, adolescents and young adult sur-
vivors. Much work has already been done in this area,
particularly by SIOPE and must be built upon.
Survivorship challenge 1.9: Lack of Focus on Pallia-
tive/End of Life research.
Recommended solution 1.9: Research in palliative
and end-of-life care is another area of unmet need.
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This requires a more comprehensive focus on promot-
ing research activities for the full spectrum of palliative
cancer patients and at all ages; (a) for those living with
a chronic cancer diagnosis under prolonged treatment;
(b) for patients in end-of-life care; and (c) for patients
with very poor prognosis, where patient-reported out-
come measures are challenging.
Survivorship challenge 1.10: Improve cancer survival
such that an average of 70% survival is achieved across
Europe by 2035 (the 70:35 vision).
Recommended solution 1.10: Support the ambition of
a 70:35 vision [14] through a European Cancer Sur-
vivorship Research and Innovation Plan that encour-
ages sharing of best practice and promotion of
survivorship research and innovation. Long-term
follow-up of patients should be a target of cancer cen-
tres involved in therapy development, in order to
implement a survivorship care plan that includes the
provision of medical and nonmedical care, while also
supporting patient’s self-management, ensuring tertiary
prevention and enhancing all aspects of HRQoL. This
should include children, adolescents and young adults
with certain rare cancers, where little progress has been
made in the last 30 years.
4.2. Addressing the Socio-Economic Cancer
Survivorship Research and Innovation Pillar
The challenges posed in the socio-economic cancer sur-
vivorship research and innovation domain and the rec-
ommended solutions proposed are outlined below:
Survivorship challenge 2.1: Lack of detailed knowl-
edge of the specific social determinants of cancer
inequalities that impact on cancer survivorship.
Recommended solution 2.1: Promote research to
identify the determinants of cancer inequalities linked
to social rehabilitation of cancer survivors of all ages,
including the disparities present across EU Member
States (in particular in Central and Eastern European
countries). Studies should be conducted to better
assess the specific impact of cancer on people’s daily
lives, in order to address their needs and target the
sources of inequalities that they are experiencing.
Survivorship challenge 2.2: Paucity of relevant tools
to assess health-related quality of life (HRQoL) in can-
cer survivors.
Recommended solution 2.2: Maximise the use of
existing tools, including comparisons between different
studies and their harmonisation, to ensure best use is
made of existing data. Create and evaluate new
research tools to accurately assess HRQoL of cancer
survivors and to identify the social determinants of
health and return to normal life.
Survivorship challenge 2.3: Lack of accurate robust
data on the economic burden of cancer for cancer sur-
vivors.
Recommended solution 2.3: Implement research that
performs precise economic evaluations of the indirect
costs (including the loss of productivity of the sur-
vivor, the social security expenditure, the costs related
to the welfare and social security protection of individ-
uals with disabling diseases and the levels of financial
toxicity experienced by survivors and their families), in
addition to direct health costs associated with sur-
vivorship, with the ability to benchmark across Euro-
pean countries and regions. Being able to guarantee an
efficient path for cancer patients to recover their
health, including supportive care, rehabilitation, pallia-
tive and psychosocial care interventions, would guar-
antee a significant reduction in costs for the social
security system, freeing up public resources that could
be used to support investment in cancer health innova-
tion. These activities (which should cover all age
groups) could align to the cancer inequality dashboard
activity proposed at the launch of the Europe Beating
Cancer Plan.
Survivorship challenge 2.4: Paucity of data on the
impact and cost-effectiveness of interventions for cancer
survivors.
Recommended solution 2.4: Evaluate the impact and
cost-effectiveness of supportive care, rehabilitation,
palliative and psychosocial care interventions on all
age groups of cancer survivors. Outcome research with
a focus on cancer survivorship should be a component
of the translation cancer research continuum and
should be integrated into all National Cancer Control
Plans (NCCP) across Europe.
Survivorship challenge 2.5: Lack of financial support
for cancer survivorship research on a European level.
Recommended solution 2.5: Elaborate proposals that
accurately define the financial commitment required to
support long-term cancer survivorship research on a
European level (In particular for CEE Countries), so
as to ensure that the appropriate level of sustainable
budget is dedicated to survivorship research and inno-
vation within the EU Cancer Mission.
Survivorship challenge 2.6: Limited integration of
social issues into cancer survivorship research activities.
Recommended solution 2.6: Promote social issues
such as access to work, education, insurance, loan,
mortgage and financial toxicity, to ensure that they are
prioritised in the cancer survivorship research and
innovation agenda. Research on social issues and fac-
tors influencing return to work should be implemented
to help safeguard cancer survivors’ working lives, their
employability, skills and capacity to work. Research
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on how skills could be offered to self-employed work-
ers to help them to achieve balance between their
health needs and work/social needs should also be
encouraged.
4.3. Addressing the Politico-Legal Cancer
Survivorship Research and Innovation Pillar
The challenges posed in the politico-legal cancer sur-
vivorship research and innovation domain and the rec-
ommended solutions proposed are outlined below:
Survivorship challenge 3.1: Limited detailed intelli-
gence on the legal aspects of discrimination for cancer
survivors.
Recommended solution 3.1: Promote studies to com-
prehensively characterise the legal aspects of discrimi-
nation for cancer survivors and use this intelligence to
inform research on discrimination against cancer
patients and how this discrimination can be mitigated.
Survivorship challenge 3.2: Lack of research on the
legal aspects of reintegration of cancer survivors back
into society.
Recommended solution 3.2: Evaluate the adoption of
legal provisions that have a key role in promoting
reintegration, equality and social inclusion and the
Right to Be Forgotten for all age groups [16,17].
Ensure that the Right to be Forgotten is adopted
across all European countries and jurisdictions.
Survivorship challenge 3.3: Need for research that
specifically focusses on the activities and requirement of
Cancer Patient Advocacy Groups.
Recommended solution 3.3: Developing research pro-
grammes dedicated to patient advocacy groups (repre-
senting childhood, adolescent and adult survivors),
including those that identify an appropriate model for
financially supporting patient advocacy research activi-
ties. This is particularly relevant in the context of the
COVID-19 pandemic, where many Patient Advocacy
Groups have experienced significant difficulties in
maintaining their activities.
Survivorship challenge 3.4: Lack of knowledge of the
stigma associated with cancer.
Recommended solution 3.4: Develop appropriate
research programmes that define the challenging stig-
mas associated with cancer, in order to promote a cul-
tural shift to a more active survivorship-focussed
campaign, spreading the key message that cancer is
not a death sentence anymore and that once cure has
been achieved, cancer survivors have the right to
return to a normal life, including the Right to be For-
gotten to avoid financial discrimination. Take advan-
tage of the existing legal framework in 4 EU countries
(France, Belgium, Luxembourg and the Netherlands)
to investigate a pan-European legal framework on
access to financial services, on the basis of equal access
for all EU cancer survivors, working closely with exist-
ing networks of professional orgaisations, patient
advocacy organisations and cancer survivors and their
families.
Survivorship challenge 3.5: Lack of specific research
on survivorship support for patients and for patient
empowerment.
Recommended solution 3.5: (A) Determine the poten-
tial role of comprehensive survivorship clinics (as exist
in the Netherlands for children with cancer) and pro-
mote these as examples of good practices to share
among EU Countries [18]. Formalise indications on
how survivorship care should be organised, whether in
specialised survivorship clinics or in rehabilitation clin-
ics or to an entirely different infrastructure that facili-
tates comprehensive and tailored long-term follow-up
of individuals.
Recommended solution 3.5: (B) Develop and provide
supports and tools (including e-health supports) to
empower patients by promoting their self-
management. Online programmes and e-health tools
can help to improve the detection and evaluation of
needs in supportive care and offer a robust alternative
for educating survivors, since they are considered cost
efficient and show equal impact with more conven-
tional approaches. Self-management programmes need
to be offered to cancer survivors that provide advice
about potential late effects and their early identifica-
tion and management.
For both 3.5 (A and B), it will be important to rea-
lise that one size does not fit all and we need to be
flexible to ensure that local situations in particular
countries or regions are taken into account. We need
to deliver for all cancer survivors, right across Europe.
5. Conclusion
In this policy paper, we build on the previous work of
the European Academy of Cancer Sciences that identi-
fied a comprehensive evidence base and indicated the
absolute need to ensure that cancer survivorship
research is recognised as a critical component of the
overall cancer research activity in Europe. Here, we
articulate the key challenges from a medical, socio-
economic and politico-legal perspective that need to be
recognised and addressed, in order to ensure that can-
cer survivorship research and innovation are firmly
embedded within the European cancer research
agenda. We propose a series of recommended solu-
tions to these challenges, which, if acted upon, will
contribute to enhance cancer outcomes and improve
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quality of life for the millions of Europeans who are
living with and beyond cancer over the next decade.
As part of our recommendations, we call for the estab-
lishment of a European Cancer Survivorship Research
and Innovation Plan. Integration of this plan within
the framework of the EU Cancer Mission would
ensure that the challenges that cancer survivors face
are clearly delineated, actively researched with sus-
tained funding through future Horizon Europe
research funding calls, leading to a greater understand-
ing of the challenges that cancer survivors experience
on a daily basis and a research-informed approach to
their resolution.
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